Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Papillomavirus Infections 5Uterine Cervical Neoplasms 3Condylomata Acuminata 2Vulvar Neoplasms 1Virus Diseases 1Vaginal Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 5Cyclophosphamide 5fludarabine 4Radiotherapy 4Irinotecan 4Mitomycin 3Interleukin-12 Subunit p35 3Fluorouracil 3Capecitabine 3Trastuzumab 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Erlotinib Hydrochloride 2Cetuximab 2Carboplatin 2tipifarnib 1tempol 1prexasertib 1oncogene protein E7, Human papillomavirus type 16 1entinostat 1Vorinostat 1Vaccines 1Thalidomide 1Taxes 1Surveys and Questionnaires 1Specimen Handling 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Papillomavirus Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Anus Neoplasms × Papillomavirus Vaccines × Clear all
NCT05680454 2023-01-17

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Beijing Health Guard Biotechnology, Inc

Phase 1 Completed
160 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡